NMN may be an effective therapy against AD

by: GSHWORLD Time: 2023-07-07 Classify: Technological Innovation

NMN, one of the precursors for the synthesis of nicotinamide adenine dinucleotide (NAD+), reduces AD brain features, including neuroinflammation, mitochondrial abnormalities, synaptic dysfunction, and cognitive impairment.

NMN is a substance that occurs naturally in the human body and is a source of cellular energy.

As people age, their NAD+ levels decline, which can lead to nuclear and mitochondrial dysfunction, which is responsible for many age-related diseases, such as neurodegenerative diseases, cancer and diabetes.

Alzheimer's disease (AD) is the most common progressive neurodegenerative disease, and its occurrence is closely related to the role of gut microbiota and its metabolites in central nervous system (CNS) diseases.

However, recent research has found that Nicotinamide Mononucleotide (NMN) may be an effective therapy against AD.

NMN has shown promise in reversing AD by reducing Aβ deposition in the brain and improving mitochondrial bioenergetics and kinetics models.

In a recent study, the researchers investigated the relationship between gut microbiota and NMN treatment in APP/PS1 transgenic ( AD) Relationships in mice.

The results showed that NMN significantly altered the gut microbial community composition in AD mice.

NMN also increased the relative abundance of short-chain fatty acid (SCFAs)-producing bacteria such as Lactobacillus and Bacteroides at the genus level by protecting gut health and improving AD.

The findings suggest that NMN may improve Alzheimer's disease by modulating the gut microbiota.

This provides new strategies for the treatment of Alzheimer's disease and highlights the critical role of the gut microbiota in Alzheimer's disease pathology.

Tag: NMN,